NCT06082570View on ClinicalTrials.gov

A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

July 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

c610 injection

Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT06082570 - A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | Biotech Hunter | Biotech Hunter